000 03404nam a22005295i 4500
001 978-3-540-74229-6
003 DE-He213
005 20161121231145.0
007 cr nn 008mamaa
008 100301s2008 gw | s |||| 0|eng d
020 _a9783540742296
_9978-3-540-74229-6
024 7 _a10.1007/978-3-540-74229-6
_2doi
050 4 _aRS400-431
072 7 _aPSB
_2bicssc
072 7 _aSCI013020
_2bisacsh
082 0 4 _a615.19
_223
245 1 0 _aAlzheimer's Disease
_h[electronic resource] /
_cedited by Lit-Fui Lau, Michael A. Brodney.
246 3 _aWith contributions by numerous experts
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2008.
300 _aXIII, 179 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aTopics in Medicinal Chemistry,
_x1862-2461 ;
_v2
505 0 _aTherapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview -- Cholinesterase Inhibitors -- Beyond Cholesterol: Statin Benefits in Alzheimer's Disease -- PPAR? Agonists for the Treatment of Alzheimer's Disease -- Metal Complexing Agents for the Treatment of Alzheimer's Disease -- GSK-3 Inhibitors for the Treatment of Alzheimer's Disease.
520 _aAlzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors). This volume will first review existing cholinesterase inhibitors prescribed for AD patients followed by some target mechanisms with ongoing clinical trials. It offers a glimpse of what our future medicine cabinets may look like for AD patients. It also provides an interesting read on why and how current medicines for other indications could potentially be used to treat AD.
650 0 _aChemistry.
650 0 _aMolecular biology.
650 0 _aPharmacology.
650 0 _aOrganic chemistry.
650 0 _aMedicinal chemistry.
650 1 4 _aChemistry.
650 2 4 _aMedicinal Chemistry.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aOrganic Chemistry.
650 2 4 _aMolecular Medicine.
700 1 _aLau, Lit-Fui.
_eeditor.
700 1 _aBrodney, Michael A.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783540742289
830 0 _aTopics in Medicinal Chemistry,
_x1862-2461 ;
_v2
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-540-74229-6
912 _aZDB-2-CMS
950 _aChemistry and Materials Science (Springer-11644)
999 _c509419
_d509419